Normandie Université, UNICAEN, ABTE, 14000 Caen, France.
Danisco Animal Nutrition, DuPont Industrial Biosciences, Marlborough SN8 1XN, UK.
Poult Sci. 2019 Jun 1;98(6):2338-2346. doi: 10.3382/ps/pey593.
Enterococcus cecorum is a commensal bacteria and opportunistic pathogen that can cause outbreaks of Enterococcal spondylitis ("kinky back") in poultry, with a growing concern worldwide. Numerous Bacillus-based probiotic strains are commercially available with proven effects in supporting gut health and growth performance, but efficacy against pathogenic E. cecorum is unknown. This study compared the in vitro inhibitory potential of cell-free supernatants (CFSs) of 18 Bacillus strains (14 commercial probiotic strains, 1 internal negative control and 3 type strains) on the growth of 9 clinical E. cecorum isolates. Standardized biomass cultures of live Bacillus were harvested and filtered to obtain CFSs. Inhibitory potential against E. cecorum isolates was assessed via a microdilution assay in which the final pathogen concentration was ∼ 104 CFU/mL. Absorbance (OD) was measured every 15 min for 15 h and used to calculate percentage growth inhibition at an OD equivalent to 0.4 in the positive control (PC) (pathogen but no CFS), and growth delay vs. PC. Growth kinetic responses of pathogen isolate-Bacillus strain combinations ranged from total pathogen inhibition to partial inhibition, lag in growth, no effect, or increased growth vs. PC. Percentage inhibition of individual isolates varied markedly among Bacillus strains, from 100% to -100% (growth promotion as recorded for the type strain) (B. amyloliquefaciens DSM7T). Five B. amyloliquefaciens CFSs produced higher average inhibition rates (>75%) than 2 out of 3 Bacillus licheniformis CFSs (-2.5, and -8.39% vs. PC, respectively) and 1 out of 2 Bacillus subtilis CFSs (7.3% vs. PC) (P < 0.05). Commercial strain 3AP4 exhibited the highest average percentage inhibition vs. PC (85.0% ± 7.9) and the most consistent inhibitory effect across pathogen isolates. The findings indicate that some commercially available poultry probiotic Bacillus strains are effective at inhibiting pathogenic E. cecorum in vitro, but effects are highly strain and pathogen isolate-dependent. Further work is required to confirm effects in vivo and isolate the inhibitory substances.
肠球菌是一种共生菌和机会性病原体,可导致家禽中肠球菌脊椎炎(“弯曲背部”)爆发,在全球范围内受到越来越多的关注。有许多基于芽孢杆菌的益生菌菌株在商业上可用于支持肠道健康和生长性能,但其对致病性肠球菌的功效尚不清楚。本研究比较了 18 株芽孢杆菌(14 株商业益生菌株、1 株内部阴性对照株和 3 株标准株)的无细胞上清液(CFS)对 9 株临床分离的肠球菌的体外抑制潜力。活芽孢杆菌的标准化生物量培养物收获并过滤以获得 CFS。通过微量稀释测定评估对肠球菌分离株的抑制潜力,其中最终病原体浓度约为 104 CFU/mL。每隔 15 分钟测量吸光度(OD)一次,共 15 小时,用于计算阳性对照(PC)(无 CFS 的病原体)中 OD 相当于 0.4 时的百分比生长抑制率,以及与 PC 相比的生长延迟。病原体分离株-芽孢杆菌株组合的生长动力学反应范围从完全抑制病原体到部分抑制、生长滞后、无影响或与 PC 相比生长增加。个别分离株的抑制率在芽孢杆菌菌株之间差异很大,从 100%到-100%(记录为标准株的生长促进)(解淀粉芽孢杆菌 DSM7T)。5 株解淀粉芽孢杆菌 CFS 的平均抑制率(>75%)高于 3 株地衣芽孢杆菌 CFS(分别为-2.5%和-8.39%)和 2 株枯草芽孢杆菌 CFS 中的 1 株(7.3%)(P<0.05)。商业菌株 3AP4 对 PC 的平均抑制率最高(85.0%±7.9),对病原体分离株的抑制效果最一致。研究结果表明,一些商业上可用于家禽的益生菌芽孢杆菌菌株在体外有效抑制致病性肠球菌,但效果高度依赖于菌株和病原体分离株。需要进一步的工作来确认体内效果并分离抑制物质。